Known targets — ChEMBL curated mechanism
BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL28201828 | 0.98 | TSHR (0.64) | TSHRSMN1; SMN2POLBCYP2D6TP53 | |
| Isopropyl Alcohol SCHEMBL5735328 | 0.89 | TSHR (0.76) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| SCHEMBL16046756 | 0.87 | TSHR (0.73) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| Alanine SCHEMBL10626231 | 0.86 | TSHR (0.64) | TSHRSMN1; SMN2POLBCYP2D6MAPK1 | |
| Alanine SCHEMBL10627958 | 0.86 | TSHR (0.64) | TSHRSMN1; SMN2POLBCYP2D6MAPK1 | |
| SCHEMBL28902110 | 0.85 | TSHR (0.70) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| Cadaverine Tartrate SCHEMBL231944 | 0.85 | TSHR (0.70) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| SCHEMBL5875401 | 0.85 | TSHR (0.70) | TSHRSMN1; SMN2POLBCYP2D6LMNA | |
| Lactic Acid SCHEMBL2447119 | 0.84 | CYP2D6 (0.49) | TSHRSMN1; SMN2CYP2D6TP53LMNA | |
| SCHEMBL16045501 | 0.83 | TSHR (0.67) | TSHRSMN1; SMN2POLBCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-53063343-A | — | — | None | — | — | JP | disclosed |
| CN-102070587-B | One kettle way prepares the method for Simvastatin | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2015-10-14 | — | — | CN | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| EP-2464644-A1 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2012-01-05 | — | — | US | disclosed |
| WO-2011018474-A1 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| JP-S5363343-A | PREPARATION OF ALPHA-PHENYLPROPIONIC ACID DERIVS. | MITSUI TOATSU CHEM INC | 1978-06-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, LDLR, PCSK9 | TSHR 1637/4885SMN1; SMN2 4854/4885POLB 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.